MEIP (MEI Pharma) Interest Coverage : No Debt ⁽¹⁾ (As of Mar. 2025)

View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. MEI Pharma's Operating Income for the three months ended in Mar. 2025 was $-2.77 Mil. MEI Pharma's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. MEI Pharma has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

MEI Pharma Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for MEI Pharma's Interest Coverage or its related term are showing as below:

MEIP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

MEIP's Interest Coverage is ranked better than
98.68% of 378 companies
in the Biotechnology industry
Industry Median: 125.165 vs MEIP: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MEI Pharma Interest Coverage Historical Data

The historical data trend for MEI Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MEI Pharma Interest Coverage Chart

MEI Pharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Interest Coverage

Get a 7-Day Free Trial

No Debt

N/A

No Debt

MEI Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Coverage	Get a 7-Day Free Trial															N/A	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of MEI Pharma's Interest Coverage

For the Biotechnology subindustry, MEI Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MEI Pharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where MEI Pharma's Interest Coverage falls into.

Save Embed

;

Save Embed

;

MEI Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MEI Pharma's Interest Coverage for the fiscal year that ended in Jun. 2024 is calculated as

Here, for the fiscal year that ended in Jun. 2024, MEI Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $25.44 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

MEI Pharma had no debt ⁽¹⁾.

MEI Pharma's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, MEI Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-2.77 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

MEI Pharma had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

MEI Pharma (NAS:MEIP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

MEI Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

0JW9:UK

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Executives

Taheer Datoo	director	181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Sujay Kango	director	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie	officer: Chief Medical Officer	C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson	10 percent owner	5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc.	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam	10 percent owner	111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File	officer: CFO and Corporate Secretary	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc	10 percent owner	2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii	director	C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130